LETIPharma already possesses a significant market share in Portugal as well, and is making important contributions to the development of immunotherapy in various markets in Latin America. Since 2001, LETIPharma has been present in the German market—the first ranking world market in this speciality—where the widespread acceptance of our products allows us to view the future commercial development of this market with optimism.

Allergic pathology is clearly increasing in the industrialised world, and LETIPharma considers that immunotherapy will have an increasingly important role in the management of such diseases. The laboratory therefore reaffirms its commitment to this activity and maintains an ambitious research and technological investment program to maximise its competitive capacity in this field over the long term.